Bliss Biopharma Out-Licenses HER2 ADC to Eisai for up to $2 Billion

Bliss Biopharma (Hangzhou), a clinical-stage ADC company, may out-license global rights (ex-China) for its HER2 ADC to Japan’s Eisai Pharma in a deal with a potential value of $2 billion. Initially, the two companies are collaborating on conducting Phase I/II clinical trials of the candidate, an eribulin-payload based ADC aimed at HER2 to treat cancers. Longer-term, Eisai holds an option to acquire rights to the drug, which would trigger the upfront and milestone payments. The HER2 ADC area is hot: four years ago, AstraZeneca in-licensed Daiichi Sankyo’s HER2 ADC candidate for $1 billion in staged upfront payments. More details....

Share this with colleagues: